Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2006-06-30
2009-02-17
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C530S387100, C530S387900, C530S388230
Reexamination Certificate
active
07491391
ABSTRACT:
An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
REFERENCES:
patent: 6060284 (2000-05-01), Bazan
patent: 6479634 (2002-11-01), Bazan
patent: 6495667 (2002-12-01), Bazan
patent: 6610285 (2003-08-01), Hirata
patent: 6632927 (2003-10-01), Adair et al.
patent: 6756481 (2004-06-01), Chirica et al.
patent: 6800460 (2004-10-01), Oppmann et al.
patent: 6835825 (2004-12-01), Bazan
patent: RE39015 (2006-03-01), Bazan et al.
patent: 7090847 (2006-08-01), Oppmann et al.
patent: 7183382 (2007-02-01), Oppmann et al.
patent: 7247711 (2007-07-01), Benson et al.
patent: 7252971 (2007-08-01), Benson et al.
patent: 7282204 (2007-10-01), Oft et al.
patent: 2003/0162261 (2003-08-01), Oppmann et al.
patent: 2004/0258686 (2004-12-01), Chirica et al.
patent: 2005/0208052 (2005-09-01), Katsikis et al.
patent: 2005/0244874 (2005-11-01), Kastelein et al.
patent: 2007/0048315 (2007-03-01), Presta
patent: WO 99/05280 (1999-02-01), None
patent: WO 99/40195 (1999-08-01), None
patent: WO 00/09552 (2000-02-01), None
patent: WO 00/53631 (2000-09-01), None
patent: WO 00/70049 (2000-11-01), None
patent: WO 01/18051 (2001-03-01), None
patent: WO 01/85790 (2001-11-01), None
patent: WO 2004/042009 (2004-05-01), None
patent: WO 2004/058178 (2004-07-01), None
patent: WO 2004/071517 (2004-08-01), None
patent: WO 2004/081190 (2004-09-01), None
patent: WO 2004/101750 (2004-11-01), None
patent: WO 2007/024846 (2007-03-01), None
Panka et al. Proc. Natl. Acad. Sci. USA vol. 85, pp. 3080-3084 (May 1988).
Rudikoff et al. Proc. Natl. Acad. Sci. USA vol. 79, pp. 1979-1983 (Mar. 1982).
Amit et al. Science, Vot. 233, pp. 747-753, (Aug. 1986).
Oppmann, et al., “Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12,” Immunity, 13: 715-725 (2000).
Peter J. Barnes, “Cytokine-directed therapies for the treatment of chronic airway diseases,” Cytokine & Growth Factor Reviews 14 (2003): 511-522 (2003).
Trinchieri, et al., “The IL-12 Family of Heterodimeric Cytokines: New Players in the Regulation of T Cell Responses,” Immunity, 19: 641-644 (2003).
Maguire van Seventer, et al., “Interferon-β differentially regulates expression of the IL-12 family members p35, p40, p19 and EB13 in activated human dendritic cells,” Journal of Neuroimmunology, 133: 60-71 (2002).
Yadav, et al., “Cytokines and autoimmunity: redundancy defines their complex nature,” Current Opinion in Immunology, 15: 697-703 (2003).
Murphy, et al., “Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation,” Journal of Experimental Medicine, 198(12): 1951-1957 (2003).
David M. Frucht, “Il-23: A Cytokine That Acts on Memory T Cells,” Science STKE, 114: 1-3 (2002).
Wiekowski, et al., “Ubiquitous Transgenic Expression of the IL-23 Subunit p19 Induces Multiorgan Inflammation, Runting, Infertility, and Premature Death,” Journal of Immunology, 166: 7563-7570 (2001).
Belladonna, et al., “IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells,” The Journal on Immunology, 168: 5448-5454 (2002).
Parham, et al., “A Receptor for the Heterodimeric Cytokine IL-23 is Composed of IL-12Rβ1 and a Novel Cytokine Receptor Subunit, IL-23R,” The Journal of Immunology, 168: 5699-5708 (2002).
Cua, et al., “Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain,” Nature, 421: 744-748 (2003).
GenBank Accession No. AF301620, Oppmann, et al., Dec. 4, 2000.
GenBank Accession No. AA418955, Hillier, et al., May 12, 1997.
GenBank Accession No. C06368, J. Takeda, Aug. 9, 1996.
GenBank Accession No. AA418747, Hillier, et al., May 12, 1997.
PCT International Search Report dated Sep. 5, 2007.
Benson Jacqueline
Cunningham Mark
Duchala Cynthia
Giles-Komar Jill M.
Luo Jinquan
Centocor, Inc.
Dichter Eric
Mertz Prema
LandOfFree
Anti-IL-23 antibodies, compositions, methods and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IL-23 antibodies, compositions, methods and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IL-23 antibodies, compositions, methods and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4088025